Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company

GL Capital and SciClone Pharmaceuticals Agree to Privatization and Delisting

Fineline Cube May 24, 2024

GL Capital and SciClone Pharmaceuticals Inc (HKG: 6600) have jointly announced an agreement to privatize...

Policy / Regulatory

NMPA Releases 80th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube May 24, 2024

The National Medical Products Administration (NMPA) has released the 80th batch of reference drugs for...

Company Drug

Sandoz Receives European Commission Approval for Biosimilars Wyost and Jubbonti

Fineline Cube May 24, 2024

The European Commission (EC) has granted registration approval to Sandoz, a Switzerland-headquartered pharmaceutical company (SWX:...

Company Deals

Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development

Fineline Cube May 24, 2024

Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and...

Company Drug

Roche’s Genentech Gets Green Light for Vixarelimab UC Clinical Trial in China

Fineline Cube May 24, 2024

Roche (SWX: ROG)’s Genentech, a leading biotechnology company based in Switzerland, has received approval to...

Company Drug

RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer

Fineline Cube May 24, 2024

RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that its antibody-drug...

Policy / Regulatory

Guangzhou Boosts Innovative Drug Development with New HSA Initiatives

Fineline Cube May 24, 2024

The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...

Company Drug

Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico

Fineline Cube May 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Company Deals

China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition

Fineline Cube May 24, 2024

Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with...

Company Drug

Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China

Fineline Cube May 24, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study

Fineline Cube May 24, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...

Company Deals

Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab

Fineline Cube May 24, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking...

Company Deals

Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals

Fineline Cube May 23, 2024

Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...

Company Deals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

Fineline Cube May 23, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...

Company Deals

Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03

Fineline Cube May 23, 2024

Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...

Company Deals

Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement

Fineline Cube May 23, 2024

China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...

Policy / Regulatory

China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations

Fineline Cube May 23, 2024

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...

Company

Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary

Fineline Cube May 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...

Company Drug

Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...

Company Drug

Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment

Fineline Cube May 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...

Posts pagination

1 … 401 402 403 … 711

Recent updates

  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
  • Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321
  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.